Neuronetics Files 8-K/A Amendment

TL;DR

Neuronetics filed an amendment to its 8-K, updating financial info. Check the details.

AI Summary

Neuronetics, Inc. filed an 8-K/A on November 13, 2024, to amend its previous filing regarding results of operations and financial condition. The amendment pertains to financial statements and exhibits, with the earliest event reported on November 12, 2024. The company is located at 3222 Phoenixville Pike, Malvern, PA.

Why It Matters

This filing is an amendment to a previous report, indicating a correction or addition to the company's financial disclosures, which could impact investor understanding of its financial health.

Risk Assessment

Risk Level: low — This is a routine amendment to a previous filing, not indicating new negative events.

Key Players & Entities

• Neuronetics, Inc. (company) — Registrant
• November 13, 2024 (date) — Filing Date
• November 12, 2024 (date) — Earliest Event Reported Date
• 3222 Phoenixville Pike, Malvern, PA (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock ($0.01 par value) STIM The Nasdaq Global M

Filing Documents

• d885367d8ka.htm (8-K/A) — 46KB
• d885367dex991.htm (EX-99.1) — 132KB
• g885367g15v25.jpg (GRAPHIC) — 19KB
• 0001193125-24-256576.txt ( ) — 342KB
• stim-20241112.xsd (EX-101.SCH) — 2KB
• stim-20241112_lab.xml (EX-101.LAB) — 17KB
• stim-20241112_pre.xml (EX-101.PRE) — 11KB
• d885367d8ka_htm.xml (XML) — 4KB

From the Filing

8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 13, 2024 ( November 12, 2024 ) NEURONETICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38546 33-1051425 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 3222 Phoenixville Pike , Malvern , PA 19355 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code ( 610 ) 640-4202 (Former name or former address, if changed since last report.) Not applicable. Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol (s) Name on each exchange on which registered Common Stock ($0.01 par value) STIM The Nasdaq Global Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. EXPLANATORY NOTE This Current Report on Form 8-K amends the Current Report on Form 8-K filed by Neuronetics, Inc. ("Neuronetics" or the "Company") on November 12, 2024 (the "Initial 8-K"), to furnish a corrected version of its press release to clarify that the Company expects to achieve cash flow breakeven by the third quarter of 2025 and is attached as Exhibit 99.1 hereto and is incorporated by reference herein. Item2.02 Results of Operations and Financial Condition. The Company issued a press release on November 12, 2024 announcing its financial results for the three months ended September 30, 2024. A copy of the press release was furnished to the Securities and Exchange Commission as Exhibit 99.1 to the Initial 8-K. The Exhibit 99.1 attached hereto is a replacement to clarify that the Company expects to achieve cash flow breakeven by the third quarter of 2025 and is incorporated by reference herein. The information furnished pursuant to Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no duty or obligation to publicly update or revise the information so furnished. "Safe harbor" statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this Current Report, include "forward-looking statements" within the meaning of U.S. federal securities laws. These forward- looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words or expressions such as "expect", "anticipate", "intend", "plan", "believe", "estimate", "may", "will", "project", "could", "should", "would", "seek", "forecast", "expect", "anticipate", "predict", "outlook", "potential", or other similar expressions, including without limitation the negative of these terms. Forward-looking statements represent current judgments about possible future events, including, but not limited to statements regarding expectations or forecasts of business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs relating to the proposed transaction between Greenbrook TMS Inc. ("Greenbrook") and Neuronetics, such as statements regarding the combined operations and prospects of Greenbrook and Neuronetics, estimates of pro forma financial information of the combined company, the current and projected market, growth oppor

View Full Filing

View this 8-K/A filing on SEC EDGAR